# V1 Empirics Check — openai/gpt-oss-120b (Variant B)

**Model:** openai/gpt-oss-120b
**Variant:** B
**Date:** 2026-03-11T21:08:44.120673

---

**Review of “The Deadline Effect: PDUFA Review Clocks and Post‑Market Drug Safety”**

---

### 1. Idea Fidelity  

The manuscript adheres closely to the original research design set out in the idea manifest.  
* **Data:** The authors use the FDA New Molecular Entity (NME) compilation (1993‑2024) and link it to openFDA FAERS, recall, and label‑warning data – exactly the three data sources proposed.  
* **Identification:** The core of the manifest calls for a “bunching estimator” (McCrary‑style density test) combined with a causal‑bunching design (or a regression‑discontinuity at the 300‑day PDUFA deadline). The paper implements the McCrary test, estimates excess mass, and runs a local‑polynomial RD. It also presents OLS comparisons of “bunched” (≈49) versus “non‑bunched” (≈126) drugs, which is the same sample window suggested (≈120‑150 observations).  
* **Research Question:** The paper investigates whether deadline‑induced timing of approvals harms post‑market safety, exactly as prescribed.  

The only notable deviation is that the manuscript does not explicitly employ a two‑stage “causal‑bunching” estimator (i.e., using the estimated excess mass as an instrument for the probability of being deadline‑bunched). Instead it relies on a direct “bunched vs. non‑bunched” comparison plus an RD. While this still exploits the same institutional manipulation, the formal causal‑bunching approach advocated in the manifest would have strengthened the link between the excess mass and the treatment effect. Nonetheless, the paper remains faithful to the spirit of the original idea.

---

### 2. Summary  

The paper exploits the conspicuous spike in FDA approvals that occur exactly at the 300‑day PDUFA standard‑review deadline to test whether such deadline‑driven timing compromises post‑market drug safety. Using the NME‑FAERS linkage, the authors find a large raw difference in adverse‑event counts for deadline‑bunched drugs, but after controlling for therapeutic class, approval year, orphan/accelerated designations and years on market the effect disappears. Both OLS with controls and a regression‑discontinuity design (though under‑powered) point to a null causal impact, suggesting that the PDUFA deadline does not degrade safety.

---

### 3. Essential Points  

1. **Limited Power in the RD Design** – The local‑polynomial RD relies on only 11 drugs on the left of the cutoff and 49–191 on the right, producing very imprecise estimates (Table 4). This raises concerns that the RD may be unable to detect a modest but policy‑relevant effect.  

2. **Covariate Imbalance at the Cutoff** – Table 9 (Panel B) shows statistically significant jumps in orphan‑drug and fast‑track status at day 300. These discontinuities contradict the claim that drug composition is smooth at the threshold and imply that the “bunched” group may be systematically different, potentially biasing the OLS estimates.  

3. **Reliance on FAERS Counts without Full Accounting for Reporting Bias** – Although the authors control for years on market, FAERS reporting intensity varies by therapeutic area, media attention, and manufacturer vigilance. The current specification does not fully address these sources of heterogeneity (e.g., by including drug‑specific reporting‑rate controls or employing a difference‑in‑differences approach anchored on pre‑approval reporting trends).

If these three issues are not satisfactorily resolved, the credibility of the causal claim is weakened. The paper should therefore be **revised** rather than rejected outright.

---

### 4. Suggestions  

Below are concrete, non‑essential recommendations that, if incorporated, will substantially improve the paper’s methodological rigor, transparency, and impact. The suggestions are ordered roughly from most urgent to more optional refinements.

#### A. Strengthening the Identification Strategy  

1. **Implement a Formal Causal‑Bunching Estimator**  
   * Follow the Saez–Kleven (2016) approach: estimate the counterfactual density of review durations, compute the excess mass \(B\), and treat \(B_i\) (the probability that a drug’s approval was shifted to the deadline) as an instrument for the binary “bunched” indicator.  
   * This two‑stage least‑squares (2SLS) framework directly links the institutional manipulation to the treatment, providing a clear causal interpretation that aligns with the original manifest.  

2. **Donut‑RD with a Wider “Clean” Bandwidth**  
   * Exclude the narrow [300, 310) window (the most manipulated observations) and compare drugs just below the deadline (e.g., 275–295 days) with those just above (305–325 days).  
   * This reduces contamination from the mechanically shifted approvals while preserving a larger number of left‑side observations, improving precision.  

3. **Alternative “Local Randomization” Test**  
   * Treat the narrow band around the deadline as a quasi‑randomized experiment (as in Lee & Lemieux, 2010). Conduct balance checks on observable covariates within, say, ±15 days of 300, and present treatment effect estimates via simple differences‑in‑means or regression adjusting for the covariates.  
   * The additional robustness test would complement the RD and reassure readers that the results are not driven by model choices.

#### B. Addressing Covariate Discontinuities  

1. **Report Full Covariate Balance Tables**  
   * Provide graphical and tabular evidence for all pre‑treatment covariates (therapeutic class, orphan status, accelerated/fast‑track, years on market, etc.) across the cutoff.  
   * If significant jumps persist, consider interacting the treatment with the affected covariates or implementing a propensity‑score matching within the RD window to equalize the composition.  

2. **Instrumental Variable for Orphan/Fast‑Track Status**  
   * If orphan or fast‑track designations are themselves potentially responsive to the deadline, model them jointly with the deadline indicator (e.g., a “joint” 2SLS where both are endogenous). This can help isolate the pure deadline effect from any selection into special pathways.

#### C. Enhancing the Use of FAERS Data  

1. **Normalize by Exposure (Drug‑Year Market Share)**  
   * Construct an exposure variable such as total prescriptions or sales volume (available from IQVIA or publicly from the FDA’s “Drug Approvals and Utilization” reports) and include it as an offset in the negative‑binomial models. This reduces bias from differential market penetration.  

2. **Employ Event‑Study / Cumulative Hazard Framework**  
   * Plot cumulative incidence of serious adverse events over calendar time since approval for bunched vs. non‑bunched drugs. A Cox proportional‑hazards model with time‑varying covariates can test whether the hazard rate diverges after the deadline while controlling for right‑censoring.  

3. **Sensitivity to Reporting Lag**  
   * FAERS reports are known to lag behind actual events; perform a lag‑adjusted analysis (e.g., exclude the first six months post‑approval) to check whether early‑reporting spikes drive the raw differences.  

#### D. Expanding the Outcome Set  

1. **Include “Time to First Black‑Box Warning”**  
   * Use survival analysis to examine whether bunched drugs receive their first boxed warning earlier (or later) than comparable drugs, which provides a more direct safety signal than raw counts.  

2. **Examine “Post‑Marketing Study” Requirements**  
   * Some FDA approvals mandate REMS or post‑marketing studies. Using the openFDA Enforcement API, compare the incidence of such requirements across groups. A higher rate for bunched drugs could indicate compensatory regulatory actions.  

#### E. Robustness and External Validity  

1. **Placebo Cutoffs with Randomly Assigned “Synthetic” Deadlines**  
   * Generate placebo cutoffs at many random days (e.g., 250, 275, 350) and report the distribution of estimated effects. This “permutation RD” approach checks whether the observed null is unique to the true deadline.  

2. **Sub‑Sample Analyses**  
   * Separate analyses by therapeutic area (e.g., oncology vs. cardiovascular) and by approval era (pre‑2007 vs. post‑2012). If the null holds across sub‑samples, the conclusion is more robust.  

3. **Assess Generalizability to Priority‑Review Drugs**  
   * Although the paper uses priority‑review drugs as a placebo test, presenting the full results (including any differences) would illuminate whether the same deadline‑effect mechanisms apply under the 180‑day deadline.  

#### F. Presentation and Transparency  

1. **Provide Replication Package**  
   * Upload the merged dataset (with de‑identified NDA numbers) and the Stata/R code used for the density test, RD, and 2SLS to the APEP GitHub repository. This will facilitate verification and future extensions.  

2. **Clarify Sample Construction**  
   * Explicitly state why only 312 of the 538 standard‑review NMEs could be linked to FAERS, and whether the missing drugs differ systematically (e.g., older drugs). If so, discuss the potential bias and perhaps conduct a sensitivity analysis assuming worst‑case reporting scenarios.  

3. **Improve Figures**  
   * Include a clear histogram of review durations with the fitted counterfactual polynomial overlaid, and a scatter plot of the RD outcome versus review days with the estimated regression line and confidence band. Visuals help readers assess the smoothness of covariates and the sharpness of the density spike.  

#### G. Minor Technical Points  

1. **Standard Errors in the RD** – Report both robust bias‑corrected and conventional robust SEs; the former can sometimes be overly conservative in small samples.  
2. **Multiple Hypothesis Testing** – Since four outcomes are examined, consider a Bonferroni or Westfall‑Young adjustment, or at least discuss the false‑positive risk.  
3. **Notation Consistency** – Align the symbols for the treatment indicator (\(D_i\)) across sections (some tables use “Bunched”, others “Treatment”).  

---

### Concluding Remarks  

The paper tackles an important policy question: whether the FDA’s legally mandated review clock harms patients. By exploiting a striking institutional bunching, the authors bring credible quasi‑experimental evidence to a debate that has largely relied on observational correlations. The core contribution—a null causal effect after appropriate controls—is valuable for regulators considering future PDUFA reauthorizations.

Nonetheless, the current specification suffers from limited RD power, observable discontinuities at the cutoff, and potential reporting biases in the FAERS outcome measures. Implementing a formal causal‑bunching estimator, refining the RD (donut or local‑randomization) design, and deepening the robustness checks around covariate balance and reporting heterogeneity will considerably strengthen the causal claim and align the analysis more closely with the original manifest’s ambition.

I recommend **major revision**. Addressing the three essential points above, together with many of the suggestions, will produce a paper that makes a solid, credible contribution to the economics of regulation and drug safety.
